Physician profile
Frederick A Boghossian
NPI 1841303849
$140,441.24
in general payments reported to CMS, 2019-2025
29 companies · $14K in 2025
The $14K reported for 2025 was more than what 94% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $29K · 2020: $12K · 2021: $22K · 2022: $19K · 2023: $28K · 2024: $17K · 2025: $14K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $54K · Food and Beverage: $5,216 · Education: $138.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $53,750.00 |
| Food and Beverage | $5,216.03 |
| Education | $137.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $120,454.59 | 2019-2025 | Creon, Linzess, Viberzi |
| Ironwood Pharmaceuticals, INC | $11,931.04 | 2019-2024 | Linzess |
| Allergan, INC. | $2,779.06 | 2019-2020 | |
| Ardelyx, INC. | $843.78 | 2022-2025 | Ibsrela |
| Janssen Pharmaceuticals, INC | $661.48 | 2019-2022 | |
| Phathom Pharmaceuticals, INC. | $562.29 | 2023-2025 | Voquezna |
| Takeda Pharmaceuticals U.S.A., INC. | $317.89 | 2019-2024 | Entyvio |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $314.15 | 2019-2025 | Trulance, Xifaxan |
| Celgene Corporation | $312.96 | 2021-2023 | Zeposia |
| Braintree Laboratories, INC. | $286.62 | 2019-2023 | Sutab |
| Madrigal Pharmaceuticals | $261.80 | 2024-2025 | Rezdiffra, Resmetirom |
| E.R. Squibb & Sons, L.L.C. | $221.43 | 2022-2023 | Zeposia |
| Gilead Sciences, INC. | $214.42 | 2020-2023 | |
| Janssen Biotech, INC. | $204.27 | 2019-2023 | Stelara |
| Merck Sharp & Dohme LLC | $197.87 | 2021-2024 | Dificid, Zinplava |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celltrion USA INC. | $150.53 | 2024-2025 | Vegzelma, Zymfentra |
| Esperion Therapeutics, INC. | $123.02 | 2022 | |
| Vivus LLC | $115.85 | 2019-2024 | Pancreaze |
| Aimmune Therapeutics, INC. | $105.38 | 2024 | |
| Redhill Biopharma INC. | $99.38 | 2020-2023 | Movantik, Aemcolo, Talicia |
| Intercept Pharmaceuticals, INC. | $62.42 | 2020-2021 | |
| Exact Sciences Corporation | $46.69 | 2023 | Cologuard Collection Kit |
| Shionogi INC | $40.78 | 2019 | |
| Qol Medical, LLC | $40.62 | 2021-2022 | |
| Medtronic, INC. | $22.76 | 2023 | Gi Genius |
| Ferring Pharmaceuticals INC. | $22.32 | 2019 | |
| W. L. Gore & Associates, INC. | $19.65 | 2022 | |
| Nestle Healthcare Nutrition INC. | $16.11 | 2023 | |
| Pfizer INC. | $12.08 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Frederick Boghossian listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.